Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-34100
Titel: | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis |
VerfasserIn: | Rosar, Florian Krause, Jonas Bartholomä, Mark Maus, Stephan Stemler, Tobias Hierlmeier, Ina Linxweiler, Johannes Ezziddin, Samer Khreish, Fadi |
Sprache: | Englisch |
Titel: | Pharmaceutics |
Bandnummer: | 13 |
Heft: | 5 |
Verlag/Plattform: | MDPI |
Erscheinungsjahr: | 2021 |
Freie Schlagwörter: | metastatic castration-resistant prostate cancer 225Ac and 177Lu PSMA radioligand therapy biochemical response molecular imaging response efficacy toxicity |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | The use of 225Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), either as monotherapy or in combination with 177Lu, is a promising therapy approach in patients with metastatic castration-resistant prostate carcinoma (mCRPC). In this study, we report the efficacy and safety of [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 RLT in 177Lu-naive mCRPC patients (n = 15) with poor prognosis (presence of visceral metastases, high total tumor burden with diffuse bone metastases or a short PSA doubling time of <2 months). Biochemical (by PSA serum value) and molecular imaging response (by [68Ga]Ga-PSMA-11 PET/CT) was assessed after two cycles of [177Lu]Lu-PSMA-617 RLT, with at least one [225Ac]Ac-PSMA-617 augmentation. In addition, PSA-based progression-free survival (PSA-PFS), overall survival (OS) and toxicity (according to CTCAE) were analyzed. We observed a biochemical- and molecular imaging-based partial remission in 53.3% (8/15) and 66.7% (10/15) of patients, respectively. The median PSA-PFS and OS was 9.1 and 14.8 months, respectively. No serious acute adverse events were recorded. Two out of fifteen patients experienced grade 3 anemia. No other grade 3/4 toxicities were observed. RLT-related xerostomia (grade 1/2) was recorded in 2/15 patients. Our data showed a high clinical efficacy with a favorable side effects profile of [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 RLT in this highly challenging patient cohort. |
DOI der Erstveröffentlichung: | 10.3390/pharmaceutics13050722 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-341007 hdl:20.500.11880/31357 http://dx.doi.org/10.22028/D291-34100 |
ISSN: | 1999-4923 |
Datum des Eintrags: | 25-Mai-2021 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Radiologie M - Urologie und Kinderurologie |
Professur: | M - Prof. Dr. Samer Ezziddin M - Keiner Professur zugeordnet |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
pharmaceutics-13-00722.pdf | 2,58 MB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons